Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.
NCT ID: NCT04954937
Last Updated: 2021-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-04-20
2022-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Donated Antibodies Working Against nCoV
NCT04429854
Convalescent Plasma Therapy for COVID-19 Patients
NCT04565197
Convalescent Plasma for COVID-19 Research Donor Study
NCT04555109
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
NCT04434131
Healthy Volunteer COVID-19 Antibody Testing Study
NCT04529460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two blood samples (9 ml total) will be collected at a local NHSBT donor centre to test the levels of the virus-neutralising antibodies in the plasma against different viral strains.
The results of this study will:
1. Determine whether NHSBT will collect CCP or plasma for medicines (PFM) from vaccinated members of the public that could have boosted antibody levels following vaccine administration.
2. Understand if antibody levels rebound to a concentration suitable for CCP and PFM.
3. Provide the evidence to support the use of CCP for the early treatment in COVID (currently under consideration as a collaboration with European partners).
4. Assist in development of recording vaccination status on NHSBT databases of donors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals who have previously donated COVID-19 convalescent plasma (CCP)
* Received at least one dose of a SARS-CoV-2 vaccine (any type of vaccine)
Exclusion Criteria
17 Years
66 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NHS Blood and Transplant
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lise Jane Estcourt
Haematologist Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lise Estcourt, MB BChir, DPhil
Role: PRINCIPAL_INVESTIGATOR
NHS Blood and Transplant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NHSBT - Birmingham Donation Centre
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21AS0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.